M
Michael D. Prados
Researcher at University of California, San Francisco
Publications - 466
Citations - 57545
Michael D. Prados is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Glioma & Temozolomide. The author has an hindex of 107, co-authored 444 publications receiving 51418 citations. Previous affiliations of Michael D. Prados include Harvard University & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide
Mei Yin C. Polley,Kathleen R. Lamborn,Susan M. Chang,Nicholas Butowski,Jennifer Clarke,Michael D. Prados +5 more
TL;DR: A strong association between the endpoints of PFS at 2, 4, and 6 months and survival is demonstrated, suggesting that 6-month PFS may be an appropriate primary endpoint in the context of phase II upfront GBM trials in the TMZ era.
Journal ArticleDOI
High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma
Susan M. Chang,Fred G. Barker,Stephen L. Huhn,M. Kelly Nicholas,Margaretta Page,Jane Rabbitt,Michael D. Prados +6 more
TL;DR: The combination of oral tamoxifen and subcutaneous interferon-alpha was associated with significant neurotoxicity in this group of recurrent glioma patients, resulting in early study closure.
Journal Article
Chromosomal Abnormalities in Glioblastoma Multiforme by Comparative Genomic Hybridization: Correlation with Radiation Treatment Outcome
Stephen L. Huhn,Gayatry Mohapatra,Andrew W. Bollen,Kathleen R. Lamborn,Michael D. Prados,Burt G. Feuerstein +5 more
TL;DR: The data suggest that GM with different in vivo responses to radiation therapy also differ cytogenetically, and this latter cytogenetic pattern was also associated with older age.
Journal ArticleDOI
The treatment of brain stem and thalamic gliomas with 78 Gy of hyperfractionated radiation therapy.
Michael D. Prados,William M. Wara,Michael S. B. Edwards,David A. Larson,Kathleen R. Lamborn,Victor A. Levin +5 more
TL;DR: For patients with brain stem or thalamic gliomas, increasing the dose of radiation therapy from 72 to 78 Gy did not significantly improve survival, and different treatment strategies are clearly needed.
Journal ArticleDOI
A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931).
Jeffrey C. Allen,Bernadine Donahue,Minesh P. Mehta,Douglas C. Miller,Lucy B. Rorke,Regina I. Jakacki,Patricia Robertson,Richard Sposto,Emi Holmes,Gilbert Vezina,Karin M. Muraszko,Diane Puccetti,Michael D. Prados,Ka Wah Chan +13 more
TL;DR: The feasibility of this intensive multimodality protocol was confirmed, and response to pre-RT CHT did not impact on survival, and survival data from this protocol can not be compared with data from other studies, given the protocol design.